Analysis of anal cancer population in a screening tertiary centre
Research type
Research Study
Full title
A retrospective descriptive analysis of a population affected by anal cancer in a tertiary referral center: from the risk factors to the management of pre-cancer lesions.
IRAS ID
231218
Contact name
Carmelina Cappello
Contact email
Sponsor organisation
HOMERTON UNIVERSITY HOSPITAL NHS TRUST
Duration of Study in the UK
0 years, 5 months, 20 days
Research summary
High grade Anal intraepithelial neoplasia(HSIL) has been recognized as precursor of anal and perianal cancer.
There are many risk factors for the development of anal cancer and some of them have been recognized by several scientific proofs: HIV positive MSM (men who have sex with men) is the group with the highest risk, but previous genital cancers and chronic iatrogenic immunosuppressive treatments are important risk factors as well. Recently few centers around the world have been grew up, where is possible to investigate risk populations for possible pre-cancer lesions by High Resolution Anoscopy (HRA) and treat them before turn into invasive cancer, of which the direct and indirect effects, due to chemo-radiotherapy treatment are well known to affect patient life.
Currently a number of different treatments are available to manage pre –cancer conditions, but the needing of good scientific evidence is mandatory, to understand better which one is best and how to choose them according to patient personal medical history. HANS service, is one of the tertiary referral centre dealing with anal cancer and pre-cancer lesions, following up at moment more than 700 patients with ano-genital high grade intraepithelial neoplasia. The aim of this research is to analyse a population of patients followed up at HANS who developed cancer, subdividing them into three groups, according to the timing they developed cancer ( if before HANS F/U, at first visits and after treatment of HSIL) to better understand, the risk factors and the difference among the subgroups, and how a closer follow up with HRA and later possible management of HSIL can be useful to avoid later stages of cancer.REC name
South Central - Hampshire B Research Ethics Committee
REC reference
17/SC/0487
Date of REC Opinion
13 Oct 2017
REC opinion
Further Information Favourable Opinion